Liraglutide

Liraglutide is a synthetic 31-amino-acid GLP-1 receptor agonist with 97 percent amino acid homology to native human GLP-1. A C-16 palmitoyl fatty acid side chain attached to lysine-26 enables binding to plasma albumin, extending the half-life to approximately 13 hours and supporting once-daily subcutaneous dosing. It is sold as Victoza (1.8 mg daily for type 2 diabetes), Saxenda (3.0 mg daily for chronic weight management), and as generic liraglutide injection (approved December 23, 2024).

The molecule was developed by Novo Nordisk in the 1990s and 2000s as the first commercially viable long-acting GLP-1 analog. Native GLP-1 has a half-life of about 1 to 2 minutes due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). The structural modifications in liraglutide (lysine substitution at position 34, palmitoyl side chain on lysine-26) protect against DPP-IV and allow albumin binding, extending the half-life roughly 600-fold compared with native GLP-1.

Victoza received FDA approval on January 25, 2010 for type 2 diabetes. Saxenda received FDA approval in December 2014 for chronic weight management. The cardiovascular indication for Victoza was added in August 2017 after the LEADER readout. Pediatric type 2 diabetes (ages 10 and older) was approved in June 2019. Pediatric obesity (ages 12 to 17) was added to Saxenda the same year. A generic liraglutide injection from Hikma was approved on December 23, 2024, ending Novo Nordisk's market exclusivity for the diabetes indication.

The Diabetes Evidence: LEAD and LEADER

The LEAD (Liraglutide Effect and Action in Diabetes) program was the original Phase 3 development for type 2 diabetes. LEAD-1 through LEAD-6 (2008 to 2010) tested liraglutide at 1.2 mg and 1.8 mg daily across multiple comparator drugs and patient populations. The trials established efficacy comparable to or better than glimepiride, exenatide, sitagliptin, and rosiglitazone, with significant weight loss as a consistent secondary finding.

The LEADER trial (Marso et al., NEJM, 2016) was the cardiovascular outcomes trial that the FDA required for the original Victoza approval. 9,340 patients with type 2 diabetes and high cardiovascular risk were randomized to liraglutide 1.8 mg daily or placebo for a median follow-up of 3.8 years. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

LEADER reported a 13 percent reduction in the primary endpoint (hazard ratio 0.87, 95% CI 0.78 to 0.97, p = 0.01). Cardiovascular death was reduced by 22 percent. All-cause mortality was reduced by 15 percent. Diabetic kidney disease was reduced by 22 percent. The Kaplan-Meier curves separated relatively early and continued to diverge over the trial period.

The LEADER results led to the August 25, 2017 FDA approval of a new indication for Victoza: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Liraglutide became the second drug after empagliflozin to gain a cardiovascular indication in type 2 diabetes from FDA-mandated CVOT data.

The Obesity Evidence: SCALE

The SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence) program evaluated liraglutide at the higher 3.0 mg dose in four Phase 3 trials enrolling more than 5,000 patients with obesity or overweight with comorbidities. The trials were the basis for the December 2014 Saxenda approval.

SCALE Obesity and Prediabetes randomized 3,731 adults with obesity or overweight (without type 2 diabetes) to liraglutide 3.0 mg or placebo for 56 weeks. Mean weight loss was 8.4 kg with liraglutide versus 2.8 kg with placebo. The 5 percent or greater weight loss threshold was reached by 63 percent of liraglutide patients versus 27 percent of placebo patients.

SCALE Diabetes in type 2 diabetes patients reported lower weight loss in the diabetic population (a recurring pattern across incretin trials).

SCALE Maintenance tested liraglutide for weight-loss maintenance after a low-calorie diet, reporting additional weight loss and lower regain rates with liraglutide.

SCALE Sleep Apnea tested liraglutide in obstructive sleep apnea, showing improvement in apnea-hypopnea index alongside weight loss.

The SCALE program established Saxenda at 3.0 mg daily as effective for chronic weight management. The weight-loss magnitudes (approximately 8 percent versus 2.6 percent placebo) are lower than what was later observed with semaglutide 2.4 mg (approximately 15 percent versus 2.4 percent in STEP-1) and tirzepatide (approximately 22 percent in SURMOUNT-1). Liraglutide is the smaller-effect GLP-1 in the obesity space.

Liraglutide binds the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the hypothalamus, the area postrema (brainstem nausea center), and several peripheral tissues. The mechanism is fundamentally the same as for semaglutide and the rest of the GLP-1 class.

In the pancreas, liraglutide stimulates glucose-dependent insulin release from beta cells. The glucose-dependent feature means insulin is only released when blood glucose is increased, which limits hypoglycemia risk when liraglutide is used as monotherapy or with metformin (without insulin or sulfonylureas).

In the brainstem and hypothalamus, GLP-1 receptor activation reduces appetite and slows gastric emptying. The appetite effect produces the weight-loss outcomes that drove the Saxenda development program. Gastric emptying slowing contributes to postprandial glucose control and contributes to early satiety.

The cardiovascular effects documented in LEADER appear to involve direct vascular effects, blood pressure reduction, reduced systemic inflammation, and the metabolic improvements that follow weight loss and glycemic control. The mechanism is partially shared with the newer GLP-1 agents.

The half-life of approximately 13 hours supports once-daily dosing. This is the key pharmacokinetic distinction from semaglutide (165 hours, once-weekly) and tirzepatide (5 days, once-weekly). For patients who prefer or require daily dosing, or who do not tolerate the higher peak concentrations of weekly agents, liraglutide remains a meaningful option.

Regulatory status

Liraglutide is FDA-approved under three product configurations: Victoza (type 2 diabetes, cardiovascular risk reduction in T2D with established CVD, pediatric T2D 10+), Saxenda (chronic weight management for adults with BMI 30+ or 27+ with weight-related condition, pediatric obesity 12+), and generic liraglutide injection (T2D only, from Hikma since December 2024). EMA approvals mirror the US indications.

The generic approval changed the pricing environment. Liraglutide list prices were approximately $1,200 to $1,500 per month at brand-name peak. The generic has reduced acquisition costs substantially in some channels, though the obesity formulation (Saxenda) and pediatric indications remain proprietary.

Liraglutide is on the WADA Prohibited List under section S4 (Hormone and Metabolic Modulators). Use in competitive sport requires a Therapeutic Use Exemption.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The cumulative safety database covers more than a decade of real-world use across millions of patients. The adverse event profile is the GLP-1 class profile.

Gastrointestinal effects dominate. Nausea, diarrhea, vomiting, and constipation are most common during dose escalation. The dose-titration schedule (start 0.6 mg daily, titrate every week to target maintenance dose) limits these effects. Most events are mild to moderate.

Acute pancreatitis at low rates across the GLP-1 class. Requires immediate discontinuation if suspected.

Gallbladder disease at modestly increased rates compared with placebo, related to rapid weight loss.

Acute kidney injury can develop in patients who become severely dehydrated from vomiting.

Thyroid C-cell tumors are the subject of a boxed warning. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome is a contraindication.

Hypoglycemia with concurrent sulfonylureas or insulin requires dose adjustment.

The cumulative GLP-1 class signal on suicidal ideation, gastroparesis, and other emerging concerns has been the subject of FDA review since 2023. No causal association has been definitively established.

The three molecules occupy different positions in the incretin class.

Liraglutide is the established daily GLP-1 with the longest cumulative real-world experience, the LEADER cardiovascular outcomes data, broadest pediatric approvals, and the lowest weight-loss magnitude. Daily dosing may suit patients who prefer fixed routines or do not tolerate weekly peak concentrations.

Semaglutide (Ozempic/Wegovy/Rybelsus) is the dominant once-weekly GLP-1. Larger weight-loss effects (approximately 15 percent at 2.4 mg, 20 percent at 7.2 mg in STEP UP), broader indication set (diabetes, obesity, cardiovascular, CKD), oral formulation available (Rybelsus).

Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist with superior weight loss versus semaglutide in SURMOUNT-5 (20.2 percent vs 13.7 percent). Approvals in diabetes, obesity, and obstructive sleep apnea.

For new starts in adult obesity and diabetes, semaglutide and tirzepatide have largely displaced liraglutide due to better efficacy and weekly dosing. Liraglutide retains a position in pediatric care (broader pediatric approvals), in patients who prefer daily dosing, and in regions where cost or formulary access favors the older molecule. The December 2024 generic approval may shift cost considerations in coming years.